FRIENDSWOOD, Texas, 17. Aug. 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), ein Unternehmen, das die Gesundheit durch innovative Tests zur Steuerung der Patientenversorgung verbessert, gab heute bekannt, dass seine Stammaktien für eine doppelte Notierung an Nasdaq Texas, einer neuen Börse mit Hauptsitz in Dallas, zugelassen wurden. Castle wird seine Primärnotierung an The Nasdaq ...
Die Zulassung erweitert den Zugang zu Castles Präzisionsmedizin-Test, der die Entscheidung über systemische Behandlungen bei Patienten mit mittelschwerer bis schwerer atopischer Dermatitis unterstützen soll FRIENDSWOOD, Texas, 14. Juli 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), ein Unternehmen, das die Gesundheit durch innovative Tests verbessert, die die Patientenversorgung ...
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram Patients classified as low risk by the i31-SLNB result had a 2.6% observed SLN positivity rate, falling well below the National Comprehensive Cancer Network (NCCN) ...
Stokes was one of 22 financial leaders recognized in the Greater Houston area FRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Frank Stokes, its chief financial officer, has been named a 2026 CFO Awards honoree by the Houston Business Journal. Stokes is amo...
FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15, 2026, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 172 employees covering an aggregate of 204,925 shares of common stock as an inducement material ...
STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled in a new study to assess flare prediction in Atopic Dermatitis. The primary objective of the multicenter prospective clinical study is to assess the prediction of flares in atopic dermatitis (AD).
FRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. Eastern time.